Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MANNITOL 20% vs MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the extracellular fluid, thereby reducing intracranial pressure and promoting diuresis.
Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into the extracellular fluid and bloodstream, thereby reducing cerebral edema and promoting diuresis. Dextrose provides a source of calories and may help prevent hypoglycemia.
Reduction of intracranial pressure and cerebral edema,Reduction of intraocular pressure,Promotion of diuresis in acute renal failure (off-label)
Reduction of intracranial pressure,Reduction of intraocular pressure,Promotion of diuresis in oliguric acute renal failure (prophylaxis or treatment),Osmotic diuresis for drug overdose (e.g., salicylates, barbiturates),Irrigation solution during transurethral prostatic resection
Adult: 50-100 g intravenously as a 20% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV over 30-60 minutes. For oliguric acute kidney injury: test dose 0.2 g/kg IV over 3-5 minutes.
Adult: 50-100 g (500-1000 m L of 10% solution) intravenously over 1-2 hours, repeated as needed every 6-12 hours. Individualize based on urine output and serum osmolality.
Terminal elimination half-life 1.1–1.6 hours in normal renal function; prolonged to 18–36 hours in anuria/end-stage renal disease.
Terminal elimination half-life of mannitol is approximately 1.5-2 hours in patients with normal renal function. Clinically, duration of osmotic diuresis parallels half-life; in renal impairment, half-life may extend to 24-36 hours, increasing risk of fluid overload and electrolyte disturbances.
Minimal hepatic metabolism; primarily excreted unchanged by the kidneys.
Mannitol is not significantly metabolized; it is excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis to pyruvate and lactic acid, and enters the Krebs cycle for energy production.
Renal, >90% unchanged by glomerular filtration; negligible biliary (<2%) or fecal elimination.
Primarily renal excretion: Mannitol is filtered by glomeruli and not reabsorbed, excreted unchanged in urine (approximately 80-90% within 24 hours). Biliary/fecal elimination is negligible (<5%). Dextrose is metabolized to CO2 and water; any excess is excreted renally as glucose if threshold exceeded.
Negligible (<0.1%); does not bind significantly to plasma proteins.
Mannitol is not significantly bound to plasma proteins (<1%). Dextrose is not protein bound.
0.25–0.4 L/kg; corresponds to extracellular fluid volume; increased in dehydration, decreased in hypervolemia.
Approximately 0.5-0.6 L/kg. Mannitol distributes primarily in extracellular fluid (ECF); it does not enter cells significantly. Clinically, this low Vd indicates confinement to ECF, important for osmotic effects.
Intravenous: 100%; oral: <10% (non-absorbed, acts as osmotic laxative).
Intravenous: 100% bioavailability. Oral bioavailability is negligible (<10%) as mannitol is poorly absorbed and acts as an osmotic laxative; Dextrose is well absorbed orally (100%) but not relevant for this IV formulation.
GFR < 50 m L/min: avoid use due to risk of volume overload and hyperosmolality. GFR 50-80 m L/min: use with caution, monitor serum osmolarity. No specific dose reduction established.
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, use with caution and monitor serum osmolality; reduce dose or extend interval. No specific dose reduction formula established.
No adjustment required for Child-Pugh class A or B. Child-Pugh class C: use with caution due to potential fluid and electrolyte imbalances; monitor closely.
No specific adjustments required for hepatic impairment. Monitor fluid and electrolyte balance due to potential volume expansion.
For cerebral edema: 0.25-1 g/kg IV as a 20% solution over 30-60 minutes. For elevated intracranial pressure: 0.25-0.5 g/kg IV. Maximum single dose typically 2 g/kg.
0.25-1 g/kg (2.5-10 m L/kg of 10% solution) intravenously over 30-60 minutes, repeated as needed. Max dose 2 g/kg/day. Adjust based on response and serum osmolality.
Elderly patients: lower initial doses (e.g., 25-50 g) recommended due to decreased renal function and higher risk of electrolyte disturbances. Monitor serum osmolarity and renal function closely.
Use lower initial doses and monitor renal function and electrolytes closely due to age-related decline in renal function and higher risk of volume overload. Start at 25-50 g (250-500 m L of 10% solution) and titrate.
None
None.
May cause volume expansion, electrolyte imbalances, and renal impairment; monitor serum electrolytes, osmolality, and renal function; use with caution in patients with heart failure or pulmonary congestion.
Monitor serum electrolytes, osmolality, and renal function during therapy,May cause fluid and electrolyte imbalances, including hyponatremia or hypernatremia,Administer cautiously in patients with renal impairment, heart failure, or pulmonary edema,Use with caution in conditions where increased intravascular volume may be harmful,Do not administer if solution contains particulate matter or is discolored
Anuria due to severe renal disease, severe pulmonary congestion or edema, active intracranial bleeding (except during craniotomy), severe dehydration, and known hypersensitivity.
Anuria due to severe renal disease,Severe dehydration,Intracranial hemorrhage (unless during craniotomy),Active intracranial bleeding except during craniotomy,Hypersensitivity to mannitol or dextrose,Congestive heart failure,Pulmonary edema
No known food interactions; however, monitor fluid and electrolyte balance as mannitol induces diuresis.
No clinically relevant food interactions.
Mannitol is not teratogenic in animal studies. In human pregnancy, there are no controlled studies; FDA pregnancy category C. First trimester: theoretical risk due to osmotic shifts, but no documented fetal harm. Second and third trimesters: use only if clearly needed; may cause maternal dehydration and electrolyte disturbances, potentially affecting fetal fluid balance. Avoid in severe maternal renal impairment.
No evidence of teratogenicity in animal studies; limited human data. Mannitol crosses the placenta; risk of fetal electrolyte disturbances and dehydration with maternal overdose. First trimester: theoretical risk only, no reported malformations. Second/third trimesters: monitor for maternal hyperosmolality and fluid shifts which may affect fetal hydration status.
Mannitol is excreted into breast milk in trace amounts; M/P ratio not established. Oral bioavailability is low, so infant exposure via breastfeeding is minimal. Compatible with breastfeeding; caution if infant has renal impairment.
Not known if mannitol or dextrose are excreted in breast milk. Consider risk of osmotic diarrhea in neonate if present in milk. M/P ratio not established.
No specific dose adjustments required; pharmacokinetics of mannitol are not significantly altered by pregnancy. Use standard dosing based on indication and renal function. Caution in preeclampsia due to potential for fluid shifts.
No specific dose adjustment recommended; monitor maternal fluid status closely as pregnancy increases risk of pulmonary edema; adjust rate based on urine output and osmolality.
Monitor serum osmolarity and sodium levels frequently; avoid use in patients with anuria, severe pulmonary congestion, or intracranial hemorrhage. Mannitol may cause acute kidney injury if used in high doses or in patients with pre-existing renal impairment. Administer via in-line filter to prevent crystallization.
Monitor serum sodium and osmolality closely; risk of hypernatremia and acute kidney injury. Use an in-line filter to prevent crystallization. Administer by slow IV infusion to avoid fluid overload. Contraindicated in anuria and severe pulmonary edema.
This medication is given intravenously to reduce swelling in the brain or to promote urine output.,Report any signs of allergic reaction, chest tightness, or difficulty breathing immediately.,You may experience increased thirst, headache, or nausea during infusion.,Inform your healthcare provider if you have kidney problems, heart failure, or are pregnant.
Report any signs of fluid overload like shortness of breath or swelling.,This medicine may cause increased urination and thirst.,Do not take this medication by mouth; it is for intravenous use only.,Inform your healthcare provider if you have kidney problems or heart failure.
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MANNITOL 20% vs MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, answered by our medical review team.
MANNITOL 20% is a Osmotic Diuretic that works by Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the extracellular fluid, thereby reducing intracranial pressure and promoting diuresis.. MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into the extracellular fluid and bloodstream, thereby reducing cerebral edema and promoting diuresis. Dextrose provides a source of calories and may help prevent hypoglycemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MANNITOL 20% and MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MANNITOL 20% is: Adult: 50-100 g intravenously as a 20% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV over 30-60 minutes. For oliguric acute kidney injury: test dose 0.2 g/kg IV over 3-5 minutes.. The standard adult dose of MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is: Adult: 50-100 g (500-1000 m L of 10% solution) intravenously over 1-2 hours, repeated as needed every 6-12 hours. Individualize based on urine output and serum osmolality.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining MANNITOL 20% and MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER. Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. MANNITOL 20% is classified as Category A/B. Mannitol is not teratogenic in animal studies. In human pregnancy, there are no controlled studies; FDA pregnancy category C. First trimester: theoretical risk due to osmotic shift. MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is classified as Category A/B. No evidence of teratogenicity in animal studies; limited human data. Mannitol crosses the placenta; risk of fetal electrolyte disturbances and dehydration with maternal overdose. F. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.